<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Abacavir and lamivudine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Abacavir and lamivudine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Abacavir and lamivudine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9010" href="/d/html/9010.html" rel="external">see "Abacavir and lamivudine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11315" href="/d/html/11315.html" rel="external">see "Abacavir and lamivudine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708583"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of abacavir/lamivudine.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients who carry the <i>HLA-B*5701</i> allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry <i>HLA-B*5701</i> allele.</p>
<p style="text-indent:-2em;margin-left:2em;">Abacavir is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in <i>HLA-B*5701</i>–positive patients. All patients should be screened for the <i>HLA-B*5701</i> allele prior to initiating therapy with abacavir/lamivudine or reinitiation of therapy with abacavir/lamivudine, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir/lamivudine immediately if a hypersensitivity reaction is suspected, regardless of <i>HLA-B*5701</i> status and even when other diagnoses are possible.</p>
<p style="text-indent:-2em;margin-left:2em;">Following a hypersensitivity reaction to abacavir/lamivudine, never restart abacavir/lamivudine or any abacavir-containing product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patients who have no history of abacavir hypersensitivity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Exacerbations of hepatitis B:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is a component of abacavir/lamivudine. Hepatic function should be closely monitored with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of antihepatitis B therapy may be warranted.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F128812"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Epzicom [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865513"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Abacavir-Lamivudine;</li>
<li>Auro-Abacavir/Lamivudine;</li>
<li>JAMP-Abacavir/Lamivudine;</li>
<li>Kivexa;</li>
<li>MYLAN-Abacavir/Lamivudine;</li>
<li>PMS-Abacavir-Lamivudine;</li>
<li>TEVA-Abacavir/Lamivudine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F995401"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral Agent</span>;</li>
<li>
<span class="list-set-name">HIV Agents (Anti-HIV Agents)</span>;</li>
<li>
<span class="list-set-name">Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>
<div class="block dop drugH1Div" id="F25574719"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Use in combination with other antiretroviral agents; evaluate gene mutation and antiretroviral resistance patterns (refer to www.IASUSA.org and <a href="/external-redirect?target_url=https%3A%2F%2Fhivdb.stanford.edu%2F&amp;token=0UTGrOKwDz%2FcgdqCCfJ7%2BDRCcJYh1XL9dcrpjPtdJG0rff6lNL8ZXoJkPMlaspoX&amp;TOPIC_ID=12684" target="_blank">https://hivdb.stanford.edu/</a> for more information).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tablet for oral suspension</i>: Abacavir 60 mg/lamivudine 30 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months weighing ≥5 kg, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Once-daily dosing<i>:</i> Abacavir 60 mg/lamivudine 30 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Fixed doses target a weight-based dose of abacavir 16 mg/kg/dose and lamivudine 8 mg/kg/dose administered once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">5 to &lt;6 kg: Oral: 1.5 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">6 to &lt;9 kg: Oral: 2 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">9 to &lt;12 kg: Oral: 3 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">12 to &lt;17 kg: Oral: 4 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">17 to &lt;20 kg: Oral: 5 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">20 to &lt;25 kg: Oral: 6 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">25 to &lt;29 kg: Oral: 7 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">29 to &lt;35 kg: Oral: 8 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:12em;">≥35 kg: Oral: 10 tablets once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Twice-daily dosing: Abacavir 60 mg/lamivudine 30 mg per tablet:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note: </b>Fixed doses target a weight-based dose of abacavir 8 mg/kg/dose and lamivudine 4 mg/kg/dose administered twice daily.</p>
<p style="text-indent:-2em;margin-left:12em;">5 to &lt;6 kg: Oral: 0.5 tablet in the morning, and 1 tablet in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">6 to &lt;9 kg: Oral: 1 tablet in the morning, and 1 tablet in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">9 to &lt;12 kg: Oral: 1.5 tablets in the morning, and 1.5 tablets in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">12 to &lt;17 kg: Oral: 2 tablets in the morning, and 2 tablets in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">17 to &lt;20 kg: Oral: 2.5 tablets in the morning, and 2.5 tablets in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">20 to &lt;25 kg: Oral: 3 tablets in the morning, and 3 tablets in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">25 to &lt;29 kg: Oral: 3.5 tablets in the morning, and 3.5 tablets in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">29 to &lt;35 kg: Oral: 4 tablets in the morning, and 4 tablets in the evening.</p>
<p style="text-indent:-2em;margin-left:12em;">≥35 kg: Oral: 5 tablets in the morning, and 5 tablets in the evening.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tablet</i>: Abacavir 600 mg/lamivudine 300 mg per tablet: Children and Adolescents weighing ≥25 kg: Oral: 1 tablet once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51011045"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 to &lt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary; monitor for hematologic toxicities.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use of combination product not recommended; see individual agents.</p></div>
<div class="block dohp drugH1Div" id="F51011046"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: Use of combination product not recommended; see individual agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment: Use of combination product is contraindicated; see individual agents.</p></div>
<div class="block doa drugH1Div" id="F128815"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9010" href="/d/html/9010.html" rel="external">see "Abacavir and lamivudine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Oral:</b> 1 tablet (abacavir 600 mg and lamivudine 300 mg) once daily as part of an appropriate combination regimen. <b>Note:</b> Abacavir and lamivudine should not be used in combination with efavirenz, raltegravir, boosted atazanavir, or boosted darunavir in patients with pretreatment HIV RNA ≥100,000 copies/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990064"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 to &lt;50 mL/minute: No dosage adjustment necessary; monitor for hematologic toxicities.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Use is not recommended (use dose-adjusted individual components).</p></div>
<div class="block doha drugH1Div" id="F50987321"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components).</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate and severe impairment (Child-Pugh class B or C): Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F128790"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. See individual agents as well as other combination products for additional information. Rates of adverse reactions were defined during combination therapy with other antiretrovirals.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Abnormal dreams, anxiety, depression, dizziness, fatigue, headache, insomnia, malaise, migraine, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, gastritis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity (including multiorgan failure and anaphylaxis; ≤9%; higher incidence in subjects carrying the HLA-B*5701 allele)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal breath sounds, alopecia, anemia (including pure red cell aplasia and severe anemias progressing on therapy), aplastic anemia, erythema multiforme, exacerbation of hepatitis B, hepatitis, hyperglycemia, immune reconstitution syndrome, increased creatine phosphokinase, lactic acidosis, liver steatosis, lymphadenopathy, myasthenia, paresthesia, peripheral neuropathy, redistribution of body fat, rhabdomyolysis, seizure, splenomegaly, Stevens-Johnson syndrome, stomatitis, weakness, wheezing</p></div>
<div class="block coi drugH1Div" id="F128803"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to abacavir, lamivudine, or any component of the formulation; patients who have the <i>HLA-B*5701</i> allele; moderate or severe hepatic impairment</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity)</p></div>
<div class="block war drugH1Div" id="F128788"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: <b>[US Boxed Warning]: Serious and sometimes fatal hypersensitivity reactions have occurred with abacavir, a component of abacavir/lamivudine. Patients who carry the <i>HLA-B*5701</i> allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the <i>HLA-B*5701</i> allele. All patients should be screened for the <i>HLA-B*5701</i> allele prior to initiating or reinitiation of therapy unless patients have had a previously documented <i>HLA-B*5701</i> allele assessment. Discontinue abacavir/lamivudine if a hypersensitivity reaction is suspected. Abacavir is contraindicated in patients who have the <i>HLA-B*5701</i> allele or in patients with a prior hypersensitivity reaction to abacavir. Reintroduction of any abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy. Such reactions can occur within hours.</b> An allergy to abacavir should be documented in the medical record of allele-positive patients. Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2019). These reactions usually include signs or symptoms from two or more of the following: Fever, skin rash, constitutional symptoms (malaise, fatigue, aches), respiratory symptoms (eg, pharyngitis, dyspnea, cough), and GI symptoms (eg, abdominal pain, diarrhea, nausea, vomiting). Other signs and symptoms include lethargy, headache, myalgia, edema, abnormal chest x-ray findings, arthralgia and paresthesia. Anaphylaxis, liver failure, renal failure, hypotension, adult respiratory distress syndrome, respiratory failure, myolysis, and death have occurred in association with hypersensitivity reactions. Physical findings (lymphadenopathy, mucous membrane lesions, and rash [maculopapular, urticarial or variable]) may occur. Erythema multiforme has also been reported. Laboratory abnormalities (eg, elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and lymphopenia) may occur. Abacavir/lamivudine should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible and regardless of <i>HLA-B*5701</i> status. Abacavir/lamivudine SHOULD NOT be restarted because more severe symptoms may occur within hours, including LIFE-THREATENING HYPOTENSION AND DEATH. If abacavir/lamivudine is restarted following an interruption in therapy not associated with symptoms of a hypersensitivity reaction, carefully evaluate the patient for previously unsuspected symptoms of hypersensitivity. Do not restart if hypersensitivity is suspected or cannot be ruled out regardless of <i>HLA-B*5701</i> status. If abacavir/lamivudine is restarted, continually monitor for symptoms of a hypersensitivity reaction. Make the patient aware that reintroduction should only take place if medical care is readily accessible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves’ disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. Female gender and obesity may increase the risk for development. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary heart disease: Use has been associated with an increased risk of MI in some cohort studies (Elion 2018; HHS [adult] 2019). Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic hepatitis B: <b>[US Boxed Warning]: Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is 1 component of abacavir/lamivudine.</b> Monitor patients closely for several months following discontinuation of therapy for chronic hepatitis B; clinical exacerbations may occur. Lamivudine-resistant HBV variants have been reported in coinfected patients using lamivudine as part of an antiretroviral regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Due to fixed dose of combination product, use is not recommended with mild hepatic impairment; use in patients with moderate or severe hepatic impairment is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Due to fixed dose of combination product, use is not recommended with renal impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duplicate therapy: Concomitant use of other abacavir or lamivudine-containing products with the fixed dose combination product should be avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Emtricitabine: Concomitant use of emtricitabine-containing products should be avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878306"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Abacavir may cause mild hyperglycemia; more common in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">The major clinical toxicity of lamivudine in pediatric patients is pancreatitis, which was reported in 14% of patients in 1 open-label, uncontrolled trial; discontinue lamivudine therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur. Use with extreme caution and only if there is no satisfactory alternative therapy in pediatric patients with a history of pancreatitis or other significant risk factors for the development of pancreatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults, including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F58965218"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Abacavir and lamivudine tablets for oral suspension: FDA approved December 2023; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Abacavir and lamivudine tablets for oral suspension are indicated for the treatment of HIV-1 infection in pediatric patients ≥3 months of age and weighing ≥5 kg.</p></div>
<div class="block foc drugH1Div" id="F3338694"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epzicom: Abacavir 600 mg and lamivudine 300 mg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Abacavir 600 mg and lamivudine 300 mg</p></div>
<div class="block geq drugH1Div" id="F128786"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F128805"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Abacavir Sulfate-lamiVUDine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600-300 mg (per each): $46.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865514"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kivexa: Abacavir 600 mg and lamivudine 300 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Abacavir 600 mg and lamivudine 300 mg</p></div>
<div class="block admp drugH1Div" id="F52612166"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Tablet for oral suspension: </i>Do not chew. May be swallowed whole or broken in half and swallowed, or may be dispersed in water for administration.</p>
<p style="text-indent:-2em;margin-left:6em;">For dispersion in water: Each dose should be prepared just prior to administration; the amount of water used depends on number of tablets needed for dose. Place the appropriate number of tablets in a container; add 10 mL of drinking water <b>per</b> tablet and 5 mL for each <sup>1</sup>/<sub>2</sub> tablet. Swirl the container or stir with a spoon until the tablets are broken up into small enough pieces to be swallowed, ~2 to 3 minutes; if needed, crush the tablet pieces with a spoon. Administer immediately; if not administered immediately, may be administered within an hour of mixing, but must be stirred or swirled again (~2 to 3 minutes) prior to administration. Discard if not administered within 1 hour. Rinse the container with volume of water similar to initial quantity (eg, ~5 to 10 mL of water per tablet) and administer to ensure entire dosage is received.</p></div>
<div class="block adm drugH1Div" id="F128800"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered with or without food.</p></div>
<div class="block hazard drugH1Div" id="F49104344"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]). </p>
<p style="text-indent:0em;margin-top:2em;">Abacavir is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>
<div class="block sts drugH1Div" id="F128810"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F7874272"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F021652s028lbl.pdf%23page%3D27&amp;token=FM2VohrK%2FsUn3NEuCXB0F9GRfK2e%2B8hG3K0CtYsxVZsys%2BVEcRARkOQpqijppeS8tt9K8NVhFifZP2pb2eWhggna%2B9v7JlYT8YKcDcSZpt1bl0IQrHUiXT6tc6WaAJ%2Bh&amp;TOPIC_ID=12684" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021652s028lbl.pdf#page=27</a>, must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.</p></div>
<div class="block usep drugH1Div" id="F53565172"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection in combination with other antiretroviral agents (Tablet for oral suspension: FDA approved in pediatric patients ≥3 months of age weighing ≥5 kg; Tablet: FDA approved in pediatric patients weighing ≥25 kg and adults); <b>Note:</b> HIV regimens consisting of <b>three</b> antiretroviral agents from at least <b>two</b> classes are strongly recommended.</p></div>
<div class="block cyt drugH1Div" id="F13298625"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F3317866"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Consider alternatives to this combination when possible. If combined, monitor for increased effects/toxicities of OCT2 substrates and consider OCT2 substrate dose reductions when appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with MATE1/2-K substrates when possible. If combined, monitor for increased MATE1/2-K substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of fexinidazole with OCT2 substrates when possible. If combined, monitor for increased OCT2 substrate toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foslevodopa: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Levomethadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May diminish the therapeutic effect of Abacavir. Abacavir may decrease the serum concentration of Methadone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of OCT1 Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Abacavir may increase the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risdiplam: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of risdiplam with MATE substrates if possible. If the combination cannot be avoided, monitor closely for adverse effects. Consider a reduced dose of the MATE substrate according to that substrate's labeling if appropriate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sorbitol: May decrease the serum concentration of LamiVUDine. Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of MATE1/2-K Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of MATE substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the MATE substrate and consider a reduced dose of the MATE substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafenoquine: May increase the serum concentration of OCT2 Substrates (Clinically Relevant with Inhibitors). Management: Avoid use of OCT2 substrates with tafenoquine, and if the combination cannot be avoided, monitor closely for evidence of toxicity of the OCT2 substrate and consider a reduced dose of the OCT2 substrate according to that substrate's labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May increase the serum concentration of LamiVUDine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52914399"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The Health and Human Services (HHS) perinatal HIV guidelines consider abacavir in combination with lamivudine to be a preferred nucleoside reverse transcriptase inhibitor combination for patients with HIV who are not yet pregnant but are trying to conceive; HLA-B*5701 allele status should be evaluated and documented as negative prior to use (HHS [perinatal] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F128806"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">HLA-B*5701 allele status should be evaluated and documented as negative prior to use; abacavir is contraindicated in all patients who are positive for the HLA-B*5701 allele, including patients who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">The Health and Human Services (HHS) perinatal HIV guidelines consider abacavir in combination with lamivudine to be a preferred nucleoside reverse transcriptase inhibitor combination for pregnant patients with HIV who are antiretroviral naive, who have had antiretroviral therapy (ART) in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). In addition, patients who become pregnant while taking abacavir/lamivudine may continue if viral suppression is effective and the regimen is well tolerated. This backbone is not recommended with atazanavir/ritonavir or efavirenz if pretreatment HIV RNA is &gt;100,000 copies/mL (HHS [perinatal] 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53565173"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">HIV: General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=12684" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral (ARV) drug-resistance testing is recommended before initiation of therapy in treatment-naive patients and before changing regimens in patients for whom treatment has failed. After initiation of or change in ARV therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HLA-B*5701</i> genotype status prior to initiating therapy or resuming therapy in patients of unknown <i>HLA-B*5701</i> status (including patients previously tolerating therapy); signs and symptoms of hypersensitivity reaction (in all patients, but especially in those untested for the <i>HLA-B*5701</i> allele).</p>
<p style="text-indent:-2em;margin-left:4em;">Screen for hepatitis B prior to starting therapy (in patients who previously demonstrated no immunity to hepatitis B). For patients with hepatitis B coinfection, monitor hepatic function and hepatitis B viral load for several months after therapy with lamivudine is stopped.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum electrolytes (including anion gap), SCr, lipid profiles, hepatic function tests (baseline and periodically with therapy or if clinical presentation indicates need); serum lactate (if clinical presentation indicates need), serum amylase (if clinical presentation indicates need).</p></div>
<div class="block pha drugH1Div" id="F128787"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nucleoside reverse transcriptase inhibitor combination. </p>
<p style="text-indent:0em;margin-top:2em;text-align:justify;">Abacavir is a guanosine analogue which is phosphorylated to carbovir triphosphate which interferes with HIV viral RNA-dependent DNA polymerase resulting in inhibition of viral replication. </p>
<p style="text-indent:0em;margin-top:2em;text-align:justify;">Lamivudine is a cytosine analog. After lamivudine is triphosphorylated, the principle mode of action is inhibition of HIV reverse transcription via viral DNA chain termination; inhibits RNA-dependent DNA polymerase activities of reverse transcriptase.</p></div>
<div class="block phk drugH1Div" id="F128802"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">One Epzicom tablet is bioequivalent, in the extent (AUC) of absorption and peak concentration, to two abacavir 300 mg tablets and two lamivudine 150 mg tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">When abacavir and lamivudine tablets for oral suspension were administered to adult volunteers, abacavir and lamivudine exposures were comparable to those achieved using separate oral solutions.</p>
<p style="text-indent:-2em;margin-left:2em;">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869359"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Abacavir lamivudina trb | Abacavir/Lamivudine Sandoz | Damaris | Kivexa | Profelvir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin aristo | Abacavir/lamivudin ratiopharm | Abacavir/lamivudin stada | Abacavir/Lamivudine Sandoz | Kivexa</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine | Abacavir/lamivudine generichealth | Abacavir/lamivudine mylan | Abacavir/lamivudine sun</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine mylan | Abacavir/Lamivudine Sandoz | Kivexa</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulfate + lamivudine | Kivexa</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine mylan | Abacavir/Lamivudine Sandoz | Kivexa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Abacavir lamivudin mepha | Abacavir/Lamivudine Sandoz | Kivexa</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin | Kivexa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir + lamivudin | Abacavir + lamivudina | Abalam | Albavir | Artevir l | Diviral | Kaviduvir | Kivexa | Lamivudina+Abacavir | Tolamid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/Lamivudin AL | Abacavir/lamivudin aristo | Abacavir/lamivudin basics | Abacavir/lamivudin betapharm | Abacavir/Lamivudin Glenmark | Abacavir/lamivudin heumann | Abacavir/Lamivudin Hexal | Abacavir/lamivudin hormosan | Abacavir/lamivudin mylan | Abacavir/lamivudin puren | Abacavir/lamivudin ratiopharm | Abacavir/lamivudin teva | Abacavir/lamivudine amarox | Abacavir/lamivudine aurobindo | Kivexa</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Abacavir &amp; lamivudina | Abacavir/lamivudina | Kivexa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin Mylan pharma | Abacavir/lamivudine accord | Abacavir/lamivudine auxilia | Abacavir/Lamivudine zentiva | Kivexa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abacavir lamivudina amneal | Abacavir/lamivudina accord | Abacavir/lamivudina aurovitas | Abacavir/lamivudina dr. reddy's | Abacavir/lamivudina edigen | Abacavir/lamivudina glenmark | Abacavir/lamivudina kern pharma | Abacavir/lamivudina mylan | Abacavir/lamivudina sandoz | Abacavir/lamivudina stada | Abacavir/lamivudina teva | Kivexa</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir and lamivudine | Abacavir sulphate and lamivudine | Abacavir+Lamivudine | Abacavir/lamivudine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine mylan | Abacavir/Lamivudine Sandoz | Abacavir/Lamivudine stada | Abakavir/lamivudin mylan pharma | Kivexa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine accord | Abacavir/lamivudine arrow | Abacavir/lamivudine biogaran | Abacavir/lamivudine EG | Abacavir/lamivudine mylan | Abacavir/Lamivudine Sandoz | Abacavir/lamivudine teva | Abacavir/Lamivudine zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin | Abacavir/lamivudin mylan | Abacavir/lamivudin sun | Abacavir/lamivudine | Abacavir/lamivudine milpharm | Abacavir/lamivudine mylan | Abacavir/lamivudine teva | Epzicom | Kivexa</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kivexa | Varistren</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine teva | Kivexa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine rowex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Abalam | Abamune L | Abec l | Albavir</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Abacavir e lamivudina doc generici | Abacavir e lamivudina dr. reddy's | Abacavir e lamivudina eg | Abacavir e lamivudina mylan | Abacavir e lamivudina sun | Abacavir e lamivudina Teva</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Epzicom | Labamicom</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulfate and lamivudine | Kivexa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin | Abacavir/lamivudin sandoz | Abacavir/Lamivudine Actiopharma | Abacavir/lamivudine auxilia | Abacavir/Lamivudine Sandoz | Abacavir/lamivudine teva | Iviverz | Iviverz accord</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin | Abacavir/lamivudine | Abacavir/lamivudine accord | Abacavir/Lamivudine zentiva | Iviverz | Kivexa</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dradena | Dym clefid | Evovex | Kivexa | Klaksv | Menaflex | Narkson | Zibindoxa</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulphate and lamivudine | Kivexa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine | Abacavir/Lamivudine Glenmark | Abacavir/lamivudine mylan | Abacavir/Lamivudine Sandoz | Abacavir/lamivudine teva | Kivexa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/Lamivudin | Abacavir/lamivudin mylan | Kivexa</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine viatris</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulfato y lamivudina</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Abacavir + Lamivudine Accord | Abacavir+Lamivudine Mylan | Abacavir+Lamivudine Sandoz | Abacavir/lamivudine teva | Iviverz | Kivexa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Abacavir and lamivudine | Epzicom</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Abacavir + Lamivudina Mylan | Abacavir + lamivudina sandoz | Abacavir + lamivudina tecnigen | Abacavir + Lamivudina Teva | Kivexa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudina aurobindo | Abacavir/lamivudina terapia | Abacavir/lamivudine mylan | Kivexa</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Abacavir+Lamivudine | Abacavir/lamivudine teva | Alaget | Kivexa</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin mylan | Abacavir/lamivudine accord | Abacavir/Lamivudine Glenmark | Abacavir/lamivudine medical valley | Abacavir/Lamivudine Sandoz | Abacavir/Lamivudine stada | Abacavir/lamivudine teva | Abacavir/Lamivudine zentiva | Abakavir/lamivudin abacus medicine | Abakavir/Lamivudin Ebb | Kivexa</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Abalam | Kivexa</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Abacavir/lamivudine macleods | Abacavir/lamivudine mylan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Kivexa</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abacavir+Lamivudine | Abalam | Kivexa</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulfate + lamivudine | Abacavir sulfate/lamivudine | Abacavir sulphate + lamivudine | Kivexa</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Auro abacavir lamivudine | Dumiva | Hetbaclam | Heteruam | Mylamba | Qulam co | Vexabax</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Abamune l baby | Kivexa</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Abacavir sulfate/lamivudine | Abacavir sulphate/lamivudine | Kivexa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Abacavir and lamivudine [prescribing information]. Hyderabad, India: Mylan Laboratories Limited; December 2023.</div>
</li>
<li>
<div class="reference">
                  Abacavir sulfate solution [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics (AAP) Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-and-lamivudine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29419568">
<a name="29419568"></a>Elion RA, Althoff KN, Zhang J, et al; American AIDS Cohort Collaboration on Research and Design of IeDEA. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. <i>J Acquir Immune Defic Syndr</i>. 2018;78(1):62-72. doi: 10.1097/QAI.0000000000001642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-and-lamivudine-pediatric-drug-information/abstract-text/29419568/pubmed" id="29419568" target="_blank">29419568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Epzicom.1">
<a name="Epzicom.1"></a>Epzicom (abacavir and lamivudine) [prescribing information]. Durham, NC: ViiV Healthcare; December 2022.</div>
</li>
<li>
<div class="reference">
                  Epivir (lamivudine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2019.</div>
</li>
<li>
<div class="reference">
                  Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. <i>Lancet</i>. 2002;359(9312):1121-1122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-and-lamivudine-pediatric-drug-information/abstract-text/ 11943262 /pubmed" id=" 11943262 " target="_blank"> 11943262 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kivexa.1">
<a name="Kivexa.1"></a>Kivexa (abacavir and lamivudine) [product monograph]. Montreal, Quebec, Canada: ViiV Healthcare ULC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17317695">
<a name="17317695"></a>Lucas A, Nolan D, and Mallal S, “HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity,” <i>J Antimicrob Chemother</i>, 2007, 59(4):591-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-and-lamivudine-pediatric-drug-information/abstract-text/17317695/pubmed" id="17317695" target="_blank">17317695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11888582">
<a name="11888582"></a>Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. <i>Lancet</i>. 2002;359(9308):727-732.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-and-lamivudine-pediatric-drug-information/abstract-text/11888582/pubmed" id="11888582" target="_blank">11888582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259. doi:10.1097/PCC.0b013e31819a383c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-and-lamivudine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf" target="_blank">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>. Updated December 18, 2019. Accessed December 18, 2019.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. April 2017. <a href="http://aidsinfo.nih.gov" target="_blank">http://aidsinfo.nih.gov</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/abacavir-and-lamivudine-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12684 Version 270.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
